Portola Pharmaceuticals announced that it has initiated a Phase 1/2 clinical study of PRT2070, a novel, oral, dual spleen tyrosine kinase and janus kinase inhibitor. The compound is being developed for patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations. PRT2070's dual mechanism of action, which targets two validated pathways for tumor survival and proliferation, has strong scientific rationale in these settings, where other compounds have failed to demonstrate clinical benefit.
- Health Care Industry
- clinical study